US 12,129,246 B1
Hydroquinazoline derivatives for the treatment of a disease or disorder
Daniela Angst, Basel (CH); Philippe Bolduc, Weymouth, MA (US); Matthew William Carson, Harvard, MA (US); Atwood Kim Cheung, Arlington, MA (US); Véronique Darsigny, Somerville, MA (US); Xiang Gao, Cambridge, MA (US); Viktor Hornak, Arlington, MA (US); Keith Jendza, Cambridge, MA (US); Rajesh Karki, Weymouth, MA (US); Ajay Kumar Lal, Boston, MA (US); Gang Liu, Waltham, MA (US); Justin Yik Ching Mao, North Reading, MA (US); Jeffrey M. McKenna, Basel (CH); Erik Meredith, Hudson, MA (US); Muneto Mogi, Waltham, MA (US); Vivek Rauniyar, Cambridge, MA (US); Liansheng Su, Winchester, MA (US); Ritesh Tichkule, Cambridge, MA (US); Shuangxi Wang, Auburndale, MA (US); Chun Zhang, Sudbury, MA (US); Liang Zhao, Lexington, MA (US); and Rui Zheng, Needham, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Feb. 28, 2024, as Appl. No. 18/589,841.
Claims priority of provisional application 63/550,180, filed on Feb. 6, 2024.
Claims priority of provisional application 63/487,756, filed on Mar. 1, 2023.
Int. Cl. C07D 403/14 (2006.01); A61K 31/517 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); C07D 239/95 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01)
CPC C07D 403/14 (2013.01) [A61K 31/517 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 239/95 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01)] 30 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof wherein:
A is NR1 or CR2R3;
R1 and R2 are each, independently H, (C3-C6)cycloalkyl, or (C6-C10)aryl, wherein the (C6-C10)aryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, —CN, —OH, —CO2H, (C1-C6)alkyl and (C3-C6)cycloalkyl;
R3 is H or (C1-C6)alkyl;
R4 is (C6-C10)aryl or a 5- or 6-membered heteroaryl comprising 1, 2, 3, or 4 heteroatoms selected from N, O, and S, wherein the (C6-C10)aryl or the 5- or 6-membered heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, —CN, —OH, —CO2H, oxo, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C1-C6)alkyl, and (C1-C6)alkyl(C3-C6)cycloalkyl;
R5 is NR8R9;
R6 is selected from H, (C1-C6)alkyl, (C3-C6)cycloalkyl, and (C3-C6)cycloalkyl-(C1-C6)alkyl;
R7 is (C3-C6)cycloalkyl or (C6-C10)aryl, wherein the (C3-C6)cycloalkyl and (C6-C10)aryl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, —CN, —OH, —CO2H, and HO2C—(C1-C6)alkyl;
R8 and R9 are each, independently H, (C1-C6)alkyl or a 3- to 6-membered heterocycle comprising 1 to 3 heteroatoms selected from N, O, and S; or
R8 and R9 together with the N to which they are bound form a 3- to 10-membered heterocycle optionally comprising 1 or 2 additional heteroatoms selected from N, O, and S, wherein the 3- to 10-membered heterocycle is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, —CN, —OH, —CO2H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl-(C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkyl-O—(C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, and a 3- to 7-membered heterocycle comprising 1 to 2 heteroatoms selected from N, O, and S; and
Ra, Rb, Rc, and Rd are each, independently H or (C1-C6)alkyl.